Saliva-based Detection of CD44

CompletedOBSERVATIONAL
Enrollment

85

Participants

Timeline

Start Date

April 14, 2017

Primary Completion Date

April 10, 2019

Study Completion Date

May 3, 2022

Conditions
Oral Cavity Squamous Cell CarcinomaOropharynx Squamous Cell CarcinomaSquamous Cell Carcinoma of the OropharynxSquamous Cell Carcinoma of the Head and Neck
Interventions
DEVICE

OncAlert

A noninvasive point of care salivary rinse test performed as 1) a one-time test for control subjects, 2) at pretreatment and post treatment 3,6, 12, and 18 month time points in oral cavity/oropharynx cancer patients

Trial Locations (4)

10010

New York University College of Dentistry, New York

21204

Greater Baltimore Medical Center, Baltimore

21231

Johns Hopkins School of Medicine, Baltimore

92093

UCSD Moores Cancer Center, La Jolla

All Listed Sponsors
collaborator

Vigilant Biosciences, Inc.

INDUSTRY

collaborator

Greater Baltimore Medical Center

OTHER

collaborator

San Diego Veterans Healthcare System

FED

collaborator

NYU Langone Health

OTHER

collaborator

Johns Hopkins University

OTHER

lead

Joseph Califano

OTHER

NCT03148665 - Saliva-based Detection of CD44 | Biotech Hunter | Biotech Hunter